Arvinas, Inc. (ARVN): Price and Financial Metrics

Arvinas, Inc. (ARVN): $67.33

2.91 (+4.52%)

POWR Rating

Component Grades














  • ARVN scores best on the Growth dimension, with a Growth rank ahead of 66.37% of US stocks.
  • The strongest trend for ARVN is in Stability, which has been heading up over the past 161 days.
  • ARVN's current lowest rank is in the Momentum metric (where it is better than 15.77% of US stocks).

ARVN Stock Summary

  • Arvinas Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 8.4% of US listed stocks.
  • For ARVN, its debt to operating expenses ratio is greater than that reported by just 7.63% of US equities we're observing.
  • With a price/sales ratio of 151.24, Arvinas Inc has a higher such ratio than 97.97% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Arvinas Inc, a group of peers worth examining would be IMTX, ACRS, ALLO, RETA, and SWTX.
  • ARVN's SEC filings can be seen here. And to visit Arvinas Inc's official web site, go to

ARVN Valuation Summary

  • In comparison to the median Healthcare stock, ARVN's EV/EBIT ratio is 187.37% lower, now standing at -25.6.
  • ARVN's price/sales ratio has moved up 136.9 over the prior 36 months.
  • Over the past 36 months, ARVN's price/sales ratio has gone up 136.9.

Below are key valuation metrics over time for ARVN.

Stock Date P/S P/B P/E EV/EBIT
ARVN 2021-08-31 202.9 7.3 -25.9 -25.6
ARVN 2021-08-30 200.5 7.2 -25.6 -25.3
ARVN 2021-08-27 201.1 7.2 -25.7 -25.4
ARVN 2021-08-26 196.4 7.0 -25.1 -24.8
ARVN 2021-08-25 199.4 7.1 -25.5 -25.2
ARVN 2021-08-24 200.4 7.2 -25.6 -25.3

ARVN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARVN has a Quality Grade of D, ranking ahead of 9.31% of graded US stocks.
  • ARVN's asset turnover comes in at 0.036 -- ranking 344th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows ARVN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.036 1 -0.601
2021-03-31 0.044 1 -0.743
2020-12-31 0.057 1 -0.721
2020-09-30 0.088 1 -0.470
2020-06-30 0.178 1 -0.396
2020-03-31 0.187 1 -0.389

ARVN Price Target

For more insight on analysts targets of ARVN, see our ARVN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $130.77 Average Broker Recommendation 1.27 (Strong Buy)

ARVN Stock Price Chart Interactive Chart >

Price chart for ARVN

ARVN Price/Volume Stats

Current price $67.33 52-week high $108.46
Prev. close $64.42 52-week low $56.59
Day low $64.88 Volume 424,842
Day high $68.15 Avg. volume 363,442
50-day MA $75.75 Dividend yield N/A
200-day MA $79.42 Market Cap 3.56B

Arvinas, Inc. (ARVN) Company Bio

Arvinas Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.

ARVN Latest News Stream

Event/Time News Detail
Loading, please wait...

ARVN Latest Social Stream

Loading social stream, please wait...

View Full ARVN Social Stream

Latest ARVN News From Around the Web

Below are the latest news stories about Arvinas Inc that investors may wish to consider to help them evaluate ARVN as an investment opportunity.

Canton Hathaway, LLC Buys Amplify Lithium & Battery Technology ETF, Raytheon Technologies ...

Investment company Canton Hathaway, LLC (Current Portfolio) buys Amplify Lithium & Battery Technology ETF, Raytheon Technologies Corp, Inc, ETFMG Prime Cyber Security ETF, Snowflake Inc, sells Amgen Inc, Palantir Technologies Inc, iShares MSCI Emerging Markets ETF, Bristol-Myers Squibb Co, The Kraft Heinz Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Canton Hathaway, LLC.

Yahoo | January 6, 2022

Arvinas Inc. (NASDAQ: ARVN) Stock Could Be An Option To Consider

Arvinas Inc. (NASDAQ:ARVN) shares, rose in value on Friday, 12/17/21, with the stock price up by 6.69% to the previous days close as strong demand from buyers drove the stock to $73.40. Actively observing the price movement in the last trading, the stock closed the session at $68.80, falling within a range of $66.64 and Arvinas Inc. (NASDAQ: ARVN) Stock Could Be An Option To Consider Read More »

Stocks Register | December 18, 2021

Arvinas, Inc. (NASDAQ:ARVN) Director Sells $5,944,498.80 in Stock

Arvinas, Inc. (NASDAQ:ARVN) Director Liam Ratcliffe sold 85,705 shares of the companys stock in a transaction dated Thursday, December 16th. The stock was sold at an average price of $69.36, for a total transaction of $5,944,498.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this []

Transcript Daily | December 18, 2021

Emerald Advisers LLC Increases Stock Position in Arvinas, Inc. (NASDAQ:ARVN)

Emerald Advisers LLC raised its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 5.9% during the 3rd quarter, Holdings Channel reports. The firm owned 284,541 shares of the companys stock after purchasing an additional 15,779 shares during the quarter. Emerald Advisers LLCs holdings in Arvinas were worth $23,384,000 at the end of the most recent reporting period. []

Dakota Financial News | December 15, 2021

Arvinas, Inc. (NASDAQ:ARVN) Shares Acquired by Royal Bank of Canada

Royal Bank of Canada increased its holdings in Arvinas, Inc. (NASDAQ:ARVN) by 38.3% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,989 shares of the companys stock after acquiring an additional 828 shares during the quarter. Royal Bank of Canadas holdings in Arvinas []

Transcript Daily | December 13, 2021

Read More 'ARVN' Stories Here

ARVN Price Returns

1-mo -13.76%
3-mo -20.71%
6-mo -29.48%
1-year -23.92%
3-year 304.38%
5-year N/A
YTD -18.03%
2021 -3.29%
2020 106.69%
2019 219.77%
2018 N/A
2017 N/A

Continue Researching ARVN

Here are a few links from around the web to help you further your research on Arvinas Inc's stock as an investment opportunity:

Arvinas Inc (ARVN) Stock Price | Nasdaq
Arvinas Inc (ARVN) Stock Quote, History and News - Yahoo Finance
Arvinas Inc (ARVN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8306 seconds.